News
SDZNY
100.91
-2.43%
-2.51
Barclays Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 2d ago
Weekly Report: what happened at SDZNY last week (1102-1106)?
Weekly Report · 4d ago
Weekly Report: what happened at SDZNY last week (1026-1030)?
Weekly Report · 11/02 09:43
AbbVie: Why I See More Upside After Q3
Seeking Alpha · 10/30 17:39
Barclays Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 10/29 07:46
Sandoz falls as headwinds in Germany prompt cautious outlook
Seeking Alpha · 10/28 17:06
Weekly Report: what happened at SDZNY last week (1019-1023)?
Weekly Report · 10/26 09:42
Weekly Report: what happened at SDZNY last week (1012-1016)?
Weekly Report · 10/19 09:43
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Seeking Alpha · 10/16 12:28
Weekly Report: what happened at SDZNY last week (1005-1009)?
Weekly Report · 10/12 09:45
Barclays Sticks to Their Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 10/12 06:27
Sandoz price target raised to CHF 60 from CHF 55 at Morgan Stanley
TipRanks · 10/06 15:55
Barclays Reaffirms Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 10/06 06:35
Weekly Report: what happened at SDZNY last week (0928-1002)?
Weekly Report · 10/05 09:45
Weekly Report: what happened at SDZNY last week (0921-0925)?
Weekly Report · 09/28 09:42
Weekly Report: what happened at SDZNY last week (0914-0918)?
Weekly Report · 09/21 09:43
Sandoz wins Canada nod for generic Ozempic; inks licensing deal for generic Hemlibra
Seeking Alpha · 09/18 12:24
mAbxience, Sandoz sign collaboration agreement for biosimilar access
TipRanks · 09/18 10:25
Sandoz Partners With Fresenius Unit mAbxience On Licensing, Development, Manufacturing And Commercialization For An Emicizumab Biosimilar Candidate
Benzinga · 09/18 10:23
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Seeking Alpha · 09/17 18:21
More
Webull provides a variety of real-time SDZNY stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZNY
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.